AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11146900 — intervention group
Group type: EXPERIMENTAL
Intervention: Propinox 20 mg
Number of subjects: 400
Study 11146900 — intervention group
Group type: EXPERIMENTAL
Intervention: Propinox 30 mg
Number of subjects: 400
Study 11146900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 9442224 — intervention group
Group type: EXPERIMENTAL
Intervention: MRM (Magnetic Resonance Myelography)
Number of subjects: 41
Study 9442224 — intervention group
Group type: COMPARATOR
Intervention: Conventional Myelography
Number of subjects: 41
Study 8103133 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia with warm reperfusion (30 patients)
Number of subjects: 60
Study 8103133 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic crossclamping (30 patients)
Number of subjects: 60
Study 3518408 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic acid (5-ASA) enema (4-g nightly retention)
Number of subjects: 18
Study 3518408 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone enema (control group)
Number of subjects: 18
Study 30242335 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50 mg, 150 mg, or 300 mg) administered subcutaneously every 3 months
Number of subjects: 10059
Study 30242335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10059
Study 27310033 — intervention group
Group type: COMPARATOR
Intervention: Control group of a brief cessation intervention
Number of subjects: 190
Study 23418746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece (STM) dental implant system
Number of subjects: 60
Study 23418746 — intervention group
Group type: COMPARATOR
Intervention: 2-piece (BRA) dental implant system
Number of subjects: 60
Study 22592097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir (FPV) with or without ritonavir (100 mg or 200 mg)
Number of subjects: 1319
Study 21058244 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative playroom (case group)
Number of subjects: 200
Study 21058244 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative waiting room)
Number of subjects: 200
Study 18514926 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (MYDICAR)
Number of subjects: 0
Study 18514926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15964290 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 400 mug, given either orally or vaginally 3 h before surgery
Number of subjects: 0
Study 15964290 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study 12693575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass chemotherapy
Number of subjects: 0
Study 12693575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clue chemotherapy
Number of subjects: 0
Study 12693575 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen chemotherapy
Number of subjects: 0
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Number of subjects: 111
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h)
Number of subjects: 111
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole 30 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Number of subjects: 111
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: LC (lansoprazole 30 mg/12 h, clarithromycin 500 mg/8 h)
Number of subjects: 111
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall triple therapy
Number of subjects: 111
Study 10091208 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 111
Study 7502549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (Salofalk, 4.5 g/day)
Number of subjects: 34
Study 7502549 — intervention group
Group type: COMPARATOR
Intervention: 6-methylprednisolone (Urbason, initial dose 48 mg/day, weekly tapering)
Number of subjects: 34
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2a interferon (2.5 or 5 MU/m2)
Number of subjects: 54
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2a interferon (10 MU/m2)
Number of subjects: 54
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with interferon antibodies
Number of subjects: 54
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without interferon antibodies
Number of subjects: 54
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high titer neutralizing antibodies
Number of subjects: 54
Study 2258142 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 54
Study 7269436 — intervention group
Group type: EXPERIMENTAL
Intervention: Health resort and sanatorium treatment
Number of subjects: 0
Study 7269436 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31883961 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar simulated UVR or narrowband UVB (311 nm) exposure
Number of subjects: 102
Study 31883961 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin type II
Number of subjects: 102
Study 31883961 — intervention group
Group type: COMPARATOR
Intervention: Skin types II and VI comparison
Number of subjects: 102
Study 31243733 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bacillus cereus PAS38 (PB)
Number of subjects: 120
Study 31243733 — intervention group
Group type: COMPARATOR
Intervention: Control (CNTL, fed with basal diet)
Number of subjects: 120
Study 31243733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (VAC, fed with basal diet and injected with NDV vaccine)
Number of subjects: 120
Study 31243733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine + Probiotic Bacillus cereus PAS38 (PBVAC)
Number of subjects: 120
Study 29293539 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a photograph of Michelle Obama's face
Number of subjects: 1223
Study 29293539 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (Comparison side of the porch)
Number of subjects: 1223
Study 26488332 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued group (mailed information regarding CRC screening choices and stool kit tests)
Number of subjects: 2208
Study 26488332 — intervention group
Group type: COMPARATOR
Intervention: Stopped group (interventions were stopped)
Number of subjects: 2208
Study 25188436 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 79
Study 25188436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 22616913 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training programme during pregnancy (aerobic and strength exercises)
Number of subjects: 121
Study 22616913 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 121
Study 20559821 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 44
Study 20559821 — intervention group
Group type: COMPARATOR
Intervention: Saccharin (placebo)
Number of subjects: 44
Study 18614482 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement only when clinically indicated
Number of subjects: 755
Study 18614482 — intervention group
Group type: COMPARATOR
Intervention: Routine care of catheter (control group)
Number of subjects: 755
Study 16602471 — intervention group
Group type: EXPERIMENTAL
Intervention: Different antibiotics (specific types not mentioned)
Number of subjects: 100
Study 11846850 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg, 1x daily for 3 days at week 2)
Number of subjects: 46
Study 11846850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 46
Study 10576495 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 43
Study 10576495 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 43
Study 10576495 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 43
Study 10576495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8880166 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic cost-effectiveness analysis
Number of subjects: 0
Study 8880166 — intervention group
Group type: COMPARATOR
Intervention: Deterministic cost-effectiveness analysis
Number of subjects: 0
Study 1984711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.25 mg/kg)
Number of subjects: 21
Study 1984711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6831292 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.08 mg.kg‐1)
Number of subjects: 0
Study 6831292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (1.5 mg.kg‐1)
Number of subjects: 0
Study 6831292 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (0.4 mg)
Number of subjects: 0
Study 6831292 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.4 mg)
Number of subjects: 0
Study 31752978 — intervention group
Group type: EXPERIMENTAL
Intervention: arriba-PPI tool (electronic decision support system)
Number of subjects: 3150
Study 31752978 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual treatment by GPs)
Number of subjects: 3150
Study 30044486 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg daily
Number of subjects: 1337
Study 30044486 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg daily
Number of subjects: 1337
Study 30044486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1337
Study 27007995 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose zonisamide at 200 mg
Number of subjects: 39
Study 27007995 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose zonisamide at 300 mg
Number of subjects: 39
Study 27007995 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose zonisamide at 400 mg
Number of subjects: 39
Study 27007995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose zonisamide at 300 mg for 14 days
Number of subjects: 39
Study 26005127 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of group music training
Number of subjects: 0
Study 26005127 — intervention group
Group type: COMPARATOR
Intervention: 1 year of music training (after a 1-year wait)
Number of subjects: 0
Study 21722193 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by two implants with ball attachments (2IBA)
Number of subjects: 110
Study 21722193 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by four implants with a triple bar (4ITB)
Number of subjects: 110
Study 21722193 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by two implants with a bar (2ISB)
Number of subjects: 110
Study 21722193 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 110
Study 20975267 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 70
Study 20975267 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 70
Study 18552624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) for 16 weeks
Number of subjects: 26
Study 18552624 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive psychotherapy (BSP) for 16 weeks
Number of subjects: 26
Study 15786427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (3 litres of polyethylene glycol)
Number of subjects: 153
Study 15786427 — intervention group
Group type: COMPARATOR
Intervention: Surgery without mechanical bowel preparation
Number of subjects: 153
Study 11963202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors administered periprocedurally
Number of subjects: 0
Study 11963202 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 0
Study 11963202 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection devices
Number of subjects: 0
Study 10357502 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 132
Study 10357502 — intervention group
Group type: COMPARATOR
Intervention: Peer support intervention
Number of subjects: 132
Study 10357502 — intervention group
Group type: COMPARATOR
Intervention: Peer support intervention (subgroup analysis)
Number of subjects: 132
Study 8577008 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (24-hour combined infusion with fat, amino acids, and glucose)
Number of subjects: 0
Study 8577008 — intervention group
Group type: COMPARATOR
Intervention: Sequential infusion (combined fat and amino acids during daytime and glucose alone during nighttime)
Number of subjects: 0
Study 8577008 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion (nutrition provided by bolus infusions during 1 hour followed by 2 hours without any infusion)
Number of subjects: 0
Study 1961129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen-progestogen therapy
Number of subjects: 62
Study 1961129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6420178 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN)
Number of subjects: 246
Study 6420178 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine or methotrexate therapy
Number of subjects: 246
Study 6420178 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 246
Study 6420178 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient PN
Number of subjects: 246
Study 31038621 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised group (UG) - home-based exercise protocol for 24 weeks
Number of subjects: 56
Study 31038621 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - usual care
Number of subjects: 56
Study 31038621 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group (SG) - supervised training for 12 weeks followed by home protocol for another 12 weeks
Number of subjects: 56
Study 28528605 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% plus Betamethasone dipropionate 0.064% aerosol foam (Cal/BD)
Number of subjects: 1104
Study 28528605 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene aerosol foam
Number of subjects: 1104
Study 28528605 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate aerosol foam
Number of subjects: 1104
Study 28528605 — intervention group
Group type: COMPARATOR
Intervention: Aerosol foam vehicle
Number of subjects: 1104
Study 28528605 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene/Betamethasone dipropionate ointment
Number of subjects: 1104
Study 28528605 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 1104
Study 27271087 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg bid
Number of subjects: 532
Study 27271087 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg bid
Number of subjects: 532
Study 27271087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 24163439 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills (TEENCOPE™)
Number of subjects: 320
Study 24163439 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education (Managing Diabetes)
Number of subjects: 320
Study 22763150 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 100 mg/week
Number of subjects: 85
Study 22763150 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 10 mg/week
Number of subjects: 85
Study 19225065 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocyanate exposure in asthmatic subjects
Number of subjects: 42
Study 19225065 — intervention group
Group type: COMPARATOR
Intervention: Control subjects exposed to isocyanates
Number of subjects: 42
Study 19225065 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (including controls)
Number of subjects: 42
Study 17453978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular capacity, pain intensity, fear of injury/movement, cognitions, and depression
Number of subjects: 221
Study 17453978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing
Number of subjects: 221
Study 17453978 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiating pain, age, and duration of complaints
Number of subjects: 221
Study 17453978 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 221
Study 17535997 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTx)
Number of subjects: 50
Study 17535997 — intervention group
Group type: COMPARATOR
Intervention: No Parathyroidectomy (no PTx)
Number of subjects: 50
Study 14695845 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 0
Study 14695845 — intervention group
Group type: COMPARATOR
Intervention: BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 0
Study 14695845 — intervention group
Group type: COMPARATOR
Intervention: Stanford V (vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone)
Number of subjects: 0
Study 11040240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adrenomedullin (5.8 pmol.kg(‐1).min(‐1))
Number of subjects: 8
Study 11040240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adrenomedullin (2.9 pmol.kg(‐1).min(‐1))
Number of subjects: 8
Study 9083899 — intervention group
Group type: EXPERIMENTAL
Intervention: Local metronidazole treatment
Number of subjects: 30
Study 9083899 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole treatment
Number of subjects: 30
Study 9083899 — intervention group
Group type: EXPERIMENTAL
Intervention: Local metronidazole combined with scaling and root planing
Number of subjects: 30
Study 9083899 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole combined with scaling and root planing
Number of subjects: 30
Study 9083899 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 30
Study 9083899 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 8409183 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-GITS
Number of subjects: 9
Study 8409183 — intervention group
Group type: COMPARATOR
Intervention: dobutamine infusion
Number of subjects: 9
Study 3535429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 819
Study 3535429 — intervention group
Group type: COMPARATOR
Intervention: TCu200Ag
Number of subjects: 819
Study 31960952 — intervention group
Group type: EXPERIMENTAL
Intervention: LBB (Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6)
Number of subjects: 25
Study 31960952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31097858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (standard protocol for 12 weeks, 3 sessions weekly for 60 minutes each)
Number of subjects: 65
Study 31097858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study 26947770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ± 0.2 IU/kg/d
Number of subjects: 60
Study 26947770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ± 0.2 IU/kg/d
Number of subjects: 60
Study 26947770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 ± 0.2 IU/kg/d
Number of subjects: 60
Study 26947770 — intervention group
Group type: COMPARATOR
Intervention: 0.6 ± 0.2 IU/kg/d, 1.0 ± 0.2 IU/kg/d, 1.4 ± 0.2 IU/kg/d
Number of subjects: 60
Study 25904424 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital stenosis group (n = 63)
Number of subjects: 141
Study 25904424 — intervention group
Group type: COMPARATOR
Intervention: Non-stenosis group (n = 78)
Number of subjects: 141
Study 25904424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 22865524 — intervention group
Group type: EXPERIMENTAL
Intervention: Securflux®
Number of subjects: 177
Study 22865524 — intervention group
Group type: COMPARATOR
Intervention: No Securflux®
Number of subjects: 177
Study 21299290 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min decision aid intervention plus an information brochure
Number of subjects: 111
Study 19430625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pretreatment (cooling + topical anesthesia + counterstimulation + distraction)
Number of subjects: 160
Study 19430625 — intervention group
Group type: COMPARATOR
Intervention: Without ice pretreatment (topical anesthesia + counterstimulation + distraction)
Number of subjects: 160
Study 16916391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitz baths
Number of subjects: 58
Study 16916391 — intervention group
Group type: COMPARATOR
Intervention: No sitz baths
Number of subjects: 58
Study 15498088 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine (once daily at dinner-time)
Number of subjects: 121
Study 15498088 — intervention group
Group type: COMPARATOR
Intervention: NPH (four times/day)
Number of subjects: 121
Study 11806071 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + CHX chip
Number of subjects: 484
Study 11806071 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 484
Study 10185376 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methods in health services research
Number of subjects: 0
Study 8066157 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 13
Study 8066157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3289511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 25
Study 3289511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31944083 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 integrons detected in 67% of 100 randomly selected MDR E. coli isolates.
Number of subjects: 198
Study 31944083 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR E. coli isolates
Number of subjects: 198
Study 30335180 — intervention group
Group type: COMPARATOR
Intervention: Health care provider advice and assistance (ARM 1)
Number of subjects: 1318
Study 30335180 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care provider advice and assistance plus village health worker (VHW) counseling (ARM 2)
Number of subjects: 1318